Functionally Significant Coumarin-Related Variant Alleles and Time to Therapeutic Range in Chilean Cardiovascular Patients

Mario Rojo, MSc1,2, Angela Margarita Roco, PhD1,3,4, Marcelo Suarez, MSc1, Maria Alejandra Lavanderos, PhD1,2, Gabriel Verón, MSc1, Maria Paz Bertoglia, PhD5, Annabella Arredondo, MD6, Elena Nieto, MD7, Juan Carlos Rubilar, MSc1, Francisca Tamayo, PCh1, Daniela Cruz, MSc7, Jessica Muñoz, MSc7, Gabriela Bravo, MSc8, Patricio Salas, MD9, Fanny Mejías, MD10, Paulo Véliz, MSc10, Gerald Godoy, MSc10, Nelson Miguel Varela, PhD1,2, G. Llull, MSc7, and Luis Abel Quiñones, PhD1,2

Abstract
Despite the development of new oral agents over the last decade, vitamin K antagonists (VKAs) remain the most widely used anticoagulants for treating and preventing thromboembolism worldwide. In Chile, the Ministry of Health indicates thatacenocoumarol should be used in preference to any other coumarin. Complications of inappropriate dosing are among the most frequently reported adverse events associated with this medication. It is well known that polymorphisms in pharmacokinetic and pharmacodynamic proteins related to coumarins (especially warfarin) influence response to these drugs. This work analyzed the impact of CYP2C9*2 (rs4244285), CYP1A2*1F (rs762551), GGCl (rs11676382), CYP2C9*3 (rs1057910), CYP4F2 (rs2108622), VKORCl (rs9923231), VKORCl (rs7294), CYP3A4*1B (rs2740574), and ABCB1 (rs1045642) polymorphisms on time to therapeutic range for oral anticoagulants in 304 Chilean patients. CYP2C9*3 polymorphisms were associated with time to therapeutic range for acenocoumarol in Chilean patients, and the CYP4F2 TT genotype, MDR1 A allele, CYP1A2 A allele, and CYP3A4 T allele are promising variants that merit further analysis. The presence of polymorphisms explained only 4.1% of time to therapeutic range for acenocoumarol in a multivariate linear model. These results improve our understanding of the basis of ethnic variations in drug metabolism and response to oral anticoagulant therapy. We hope that these findings will contribute to developing an algorithm for VKA dose adjustment in the Chilean population in the near future, decreasing the frequency of stroke, systemic embolism, and bleeding-related adverse events.

1 Laboratory of Chemical Carcinogenesis and Pharmacogenetics, Department of Basic and Clinical Oncology, Faculty of Medicine, University of Chile, Santiago, Chile
2 Latin American Network for Implementation and Validation of Clinical Pharmacogenomics Guidelines (RELIVAF-CYTED), Madrid, Spain
3 Faculty of Life Sciences, Biochemistry Department, Andrés Bello University, Santiago, Chile
4 Western Metropolitan Health Service, Santiago, Chile
5 Institute of Population Health, University of Chile, Santiago, Chile
6 Institute of Public Health, Andrés Bello University, Santiago, Chile
7 San Juan de Dios Hospital, Santiago, Chile
8 Curacaví Hospital, Curacaví, Chile
9 Dr. Salvador Allende G. Health Center, Santiago, Chile
10 San José de Melipilla Hospital, Melipilla, Chile

Corresponding Authors:
Luis Abel Quiñones, Laboratory of Chemical Carcinogenesis and Pharmacogenetics (CQF), Department of Basic and Clinical Oncology, Faculty of Medicine, University of Chile, P.O. Box 70111, Santiago, Chile. Email: lquinone@med.uchile.cl
Angela Margarita Roco, Western Metropolitan Health Service, Av. Alameda Bernardo O’Higgins 2429, Santiago, Chile. Email: angela.roco@redsalud.gov.cl

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Introduction

Cardiovascular disease (CVD), the leading cause of death worldwide, includes a group of disorders of the heart and blood vessels, such as hypertension, coronary heart disease and myocardial infarction, cerebrovascular disease and stroke, peripheral vascular disease, heart failure, rheumatic heart disease, congenital heart disease, and various cardiomyopathies. An estimated 17.9 million people die from CVD each year, 85% due to heart attack or stroke,1 and deaths are projected to reach 23.6 million per year by 2030. Most CVD can be prevented by addressing behavioral risk factors (such as tobacco use, diet, physical activity, and alcohol abuse).1,2 In Chile, CVD (ICD-10 I00-I99) accounted for 27.6% of total mortality in 2016, representing 28 148 deaths, at a rate of 154.73 per 100 000 inhabitants (158.69 and 150.85 in males and females, respectively). These deaths were mainly due to stroke (8603 deaths, 48.28/100 000 inhabitants) and acute myocardial infarction (8102 deaths, 45.47/100 000 inhabitants).3 The pathophysiology of CVD is partly based on failure of the hemostatic response. Activation of factors II, VII, IX, and X in this coagulation cascade depends on the vitamin K cycle, which consists of 2 enzymes, vitamin K epoxide reductase C1 (VKORC1), responsible for metabolizing vitamin K epoxide to its reduced form (hydroquinone), and reduced vitamin K, a cofactor of the enzyme gamma-glutamyl carboxylase (GGCx), whose function is to activate coagulation factors II, VII, IX, and X through posttranslational modification, carboxylating glutamyl residues to gamma-carboxyglutamyl acid residues on these factors and generating vitamin K epoxide. In parallel, the CYP4F2 isoenzyme metabolizes reduced vitamin K for excretion through the urine, thereby decreasing the reduced vitamin K available in the cycle.4 Vitamin K antagonists (VKAs) or coumarin (acenocoumarol and warfarin) drugs competitively inhibit VKORC1 due to their structural similarity to vitamin K epoxide, preventing its binding to the active site. This inhibition decreases reduced vitamin K production and consequently lowers active II, VII, IX, and X factors levels, effectively inhibiting the coagulation cascade.5,6 Vitamin K antagonists are administered in weekly doses and adjusted based on the patient’s international normalized ratio (INR) values, which are measured at each visit. The target anticoagulation level for a given patient, expressed as an INR range, depends on the pathology for which therapy was indicated.7,8 It may take 6 months or longer to achieve a stable therapeutic range, defined as 3 consecutive visits with a therapeutic INR value at the same dose.9,10

Vitamin K antagonists have a narrow therapeutic margin, and there are many variables that influence their efficacy, such as consumption of green leafy vegetables (which are high in vitamin K), use of CYP2C9-agonist/antagonist drugs, and genetic factors.11 Complications of inappropriate dosing of coumarin drugs, particularly warfarin, are among the adverse events most frequently reported to the US Food and Drug Administration and one of the most common reasons for emergency consultations associated with such medications.12 Bleeding is the most common complication of antithrombotic therapy and predicts future cardiovascular events. Although the mechanisms that link acute hemorrhage with these later episodes are not well understood, bleeding prevention can be expected to decrease related morbidity and mortality.13 These complications might be decreased with a lower time to therapeutic range (TtTR) through proper adjustment of coumarin therapy.

Pharmacogenetic studies have assessed the relationship between genetic factors and required coumarin or VKA dose. The most studied polymorphisms include CYP2C9*2 (rs1799853), CYP2C9*3 (rs1057910), CYP4F2 (rs2108622), vitamin K epoxide reductase complex subunit 1 (VKORC1, rs9923231 and rs7294), gamma-glutamyl carboxylase (GGCx rs11676382), and P-glycoprotein (P-gp), the product of multidrug resistance gene 1 (MDR1, ABCB1 rs1045642), which plays a key role in metabolism of oral anticoagulants.14-18 Polymorphisms in enzymes VKORC1, GGCX, CYP2C9, CYP4F2, CYP3A4, CYP1A2, CYP2C19, and MDR1 affect response to a given VKA dose in patients treated with oral anticoagulants.19,20 Thus, the main objective of this study was to determine the frequencies of these genetic polymorphisms in a representative group of Chilean patients and their relationship with time to therapeutic dose of VKA. These findings could be useful in developing a pharmacogenomic algorithm for coumarin medications in the Chilean population.

Methods

Study Design and Sample Size

This retrospective study assessed patients treated with the VKA acenocoumarol as an antithrombotic at the Western Metropolitan Health Service in the Santiago and Melipilla provinces of Chile. International normalized ratio measurements were performed with a capillary sample using CoaguChek pro II equipment (Roche Mannheim, Germany). The sample size was determined according to the frequency of variant allele carriers in the population under study, using PS Power and Sample Size Calculations Version 3.0, 2009.

Patients

Blood samples were obtained from 279 patients aged 18 years or older. The study was approved by the Western Metropolitan Health Service Ethics Committee (protocol 027/2016), and all

Keywords
coumarin, acenocoumarol, VKA, polymorphisms, pharmacogenetics

Date received: 25 November 2019; accepted: 02 February 2020.
study activities were performed in compliance with in the Declaration of Helsinki (Declaration of Helsinki, 1964), Chilean laws 20.120, 20.584, and 19.628, and the Good Clinical Practices guidelines. All participants signed a written consent form. Recruitment was performed from June 2016 until December 2017. Table 1 shows the general characteristics of the study population.

Data Collection and Calculation of TtTR

Patient data were obtained from clinical centers and managed with the statistical module of the anticoagulant treatment dosing software TAONet (Roche Diagnostics, Mannheim, Germany). Patient-level TtTR was estimated by assigning in-range INR values to each day between 3 consecutive in-range readings by linear interpolation, as described by Rosendaal et al.21

Genotyping

Potentially functional single-nucleotide polymorphisms (SNP) encoding the proteins related to coumarin response were obtained from the NCBI dbSNP database (https://www.ncbi.nlm.nih.gov/snp) and SNPinfo Web Server (https://snpinfo.niehs.nih.gov) based on the level of evidence for each SNP. Genomic DNA was isolated from peripheral blood samples from patients using the High Pure PCR Template Preparation Kit (Catalog Number, 11796828001; Roche Diagnostics GmbH, Mannheim, Germany). CYP2C19*2 (rs24428435), CYP1A2*1F (rs762551), GGCx (rs11676382), CYP2C9*2 (rs1799853), CYP2C9*3 (rs1057910), CYP4F2 (rs2108622), VKORC1 (rs9923231), VKORC1 (rs7294), CYP3A4*7B (rs2740574), and ABCB1 (rs1045642) were analyzed using the TaqMan SNP Genotyping Assay (catalog number 4362691; Thermo Fisher Scientific, Waltham, Massachusetts) in a Stratagene Mx3000p real-time PCR system (Agilent Technologies, Santa Clara, California). For quality assurance, we repeated the analysis on a randomly selected 20% of samples. The context sequences for the TaqMan probes and descriptions of each polymorphism are shown in Table 2.

Statistical Analyses

We performed a Mann-Whitney U analysis to evaluate TtTR by genotype. We then developed a multivariate linear regression model using variables with a value $P \leq 0.2$ (cutoff) in the univariate analysis to adjust the $R^2$. All comparative studies were assayed by testing 3 genetic models of inheritance (dominant, codominant, and recessive), choosing the parameters with the optimal statistical association for each analysis. We used Stata software, version 12.0 (StataCorp LP, College Station, Texas) for all tests. A $P$ value of $\leq 0.05$ was considered statistically significant. We did not evaluate for Hardy-Weinberg equilibrium (HWE) as our sample does not meet basic conditions for HWE. The patients do not represent a random sample from a random mating population, a control group, or the general population; rather, the group was selected for disease. This point is significant as the SNP under study may also be related to susceptibility to cardiovascular disorders.

Table 1. Baseline Characteristics of Patients.a

| Characteristics                          | n (%)   | SD (min–max) |
|-----------------------------------------|---------|--------------|
| Men, n (%)                              | 152 (54.48%) | 345.80 (30–2351) |
| Age, years ± SD                         | 66.49 ± 14.11 | 5.77 |
| Body Mass index, kg/m² ± SD             | 29.32 ± 5.77 | 34.80 (30-2351) |

Median TtTR (interquartile range) 229

Average TtTR, days

Abbreviations: INR, international normalized ratio; SD, standard deviation.

Table 2. Context Sequences for TaqMan Probes, Used in This Study.a

| Polymorphism (rs number) | Context Sequences                                      |
|--------------------------|--------------------------------------------------------|
| ABCB1 (rs1045642)        | 5’TGTTGGCCTCTTTGTGCGCTCCCTAC[A/G]ATCTCTTTCTGTGACACCAACCACCGGC-3’ |
| CYP1A2*1F (rs5762551)    | 5’CCCTGGACACCCTGCCAGGTTCCGCGCCACCA[CT/T]AGCTGGTGTGTAATGGCTCCG-3’ |
| CYP2C19*2 (rs42442852)   | 5’TGCTCAAAGGTTGAGCTCTGTGAGG[C/A]ACAGAGCCATGTTAGATGGAGCTTA-3’ |
| CYP2C9*2 (rs1799853)     | 5’TTCCTAATCTATGATATTTCCTCC[A/G]GGAACCATAACAAATTTTAAAA-3’ |
| CYP2C9*3 (rs1057910)     | 5’GATGGGAAAGGACAGAGAGTATCAAGGAC[CT/T]GTTGTAAAGGAGAACCCGGCTCCCT-3’ |
| CYP3A4*1B (rs2740574)    | 5’TTGCTGAGGTTCCAGAGGTCAGATACGA[C/A]TTGACCTTCTCCACCACGCTTCGC-3’ |
| GGCx (rs11676382)        | 5’TAAATCTATTTATATGCCCTCTATCCTCC[CT/T]GTTGATGTGATATGACGATGAC-3’ |
| VKORC1 (rs9923231)       | 5’CTGCTGAGGTTCCAGAGGTCAGATACGA[C/A]TTGACCTTCTCCACCACGCTTCGC-3’ |
| VKORC1 (rs7294)          | 5’GGCCACATTGGTCCATTGATGTGTTGTTCGATTTTCCACGCTTC-3’ |

*aBrackets parentheses indicate the position of the polymorphism in study.
Table 4 shows the comparative analysis for TtTR by geno-
type. As described earlier, the relationship between the 10 SNP
and TtTR was assessed using 3 different inheritance models,
namely, codominant, where each genotype is assumed to have
a different and nonadditive comparative risk; dominant, where
a single copy of the SNP is assumed to be sufficient to modify
the risk; and recessive, where 2 copies are assumed to be nec-
essary to modify risk. Only the CYP2C9*3 (rs1057910) A
allele was found to be statistically associated with higher TtTR,
in the codominant (P = .026) and dominant models (P = .014).
However, the CYP4F2 TT genotype, MDR1 A allele, and
CYP3A4 T allele showed promising associations that merit
further study (P = .069, P = .066, and P = .078, respectively).

After a forward stepwise procedure, using P < .2 as the
cutoff, a multivariate linear regression analysis was performed.
Table 5 shows results of this analysis, which included the
MDR1 (rs1045642), CYP4F2 (rs2108622), CYP3A4*1B (rs2740574),
and CYP2C9*3 (rs1057910) variant alleles. The model explained only 4.12%
of the variation in TtTR (adjusted R²) in the population studied.

Discussion
The indicator most often used to evaluate the efficacy of oral
anticoagulant treatment is time in therapeutic range (TTR). A
study on the prognostic role of TTR in patients treated with
coumarins indicated that rates of stroke, systemic embolism,
and bleeding were significantly lower in patients with a TTR
above 65%, which also translated to lower mortality. The
National Institute for Health and Care Excellence recommends
a TTR above 65%, and the European Society of Cardiology
recommends a target of at least 70% for optimal anticoagula-
tion control with VKA drugs. In Chile, few studies have
characterized patients treated with coumarin derivatives. How-
ever, the GARFIELD-AF study, which assessed Chilean
patients with atrial fibrillation, reported in 2017 that the median
TTR was 40% for 971 patients treated in several public hospi-
tals and private clinics. In a previous work, we reported that
acenocoumarol is the most widely used anticoagulant in Chile
(representing 87.8% of anticoagulant prescriptions) and that
the median TTR was 50% for patients being treated with oral
anticoagulants in the Western Metropolitan Health Service net-
work. These 2 TTR values fall below standards for adequate
anticoagulation control.

In this study, we examined whether genetic polymorphisms
might influence TtTR in Chilean patients treated with aceno-
coumarol, as starting dosage might be defined more accurately
using pharmacogenetics tools. It is well known that patients
whose initial dosage is based on a genotype-guided algorithm
require less time to reach the therapeutic range and spend more
time within range than patients who receive a standard dose
without this tool. After a forward stepwise procedure, using P < .2 as the
cutoff, a multivariate linear regression analysis was performed.
Table 5 shows results of this analysis, which included the
MDR1 (rs1045642), CYP4F2 (rs2108622), CYP3A4*1B (rs2740574),
and CYP2C9*3 (rs1057910) variant alleles. The model explained only 4.12%
of the variation in TtTR (adjusted R²) in the population studied.

Table 3. Genotype and Allele Frequencies in Patients.a

| Genotype   | n  | GA | AA | CC | CT | TT |
|------------|----|----|----|----|----|----|
| VKORC1 (rs9923231) | 79 | 143 | 57 | 231 | 48 | 18 |
| CYP2C9*2 (rs1799583) | 28.32 | 51.25 | 20.43 | 82.80 | 17.20 | 0 |
| CYP4F2 (rs2108622) | 26.80 | 17.20 | 0 | 164 | 97 | 18 |
| MDR1 (rs1045642) | 37 | 135 | 107 |

| Allele frequency | G 0.54 | C 0.91 | T 0.99 |
|------------------|--------|--------|--------|
| VKORC1 (rs7294) | 260 | 17 | 2 |
| CYP2C9*3 (rs1057910) | 93.19 | 6.09 | 0.72 |
| GGCx (rs11676382) | 261 | 18 | 0 |
| CYP2C19*2 (rs4244285) | 93.55 | 6.45 | 0.72 |

| Allele frequency | C 0.69 | C 0.96 | T 0.31 |
|------------------|--------|--------|--------|
| CYP3A4*1B (rs2740574) | 248 | 29 | 2 |
| CYP1A2*1F (rs762551) | 6.09 | 37.99 | 55.91 |

- = 279.
Table 4. Relationship of the Genotypes in Study and the Days that Elapsed to Achieve a Dose Adjusted.\(^a\)

| Polymorphism | Genotype  | N    | Median Days to Reach Therapeutic Range b ± IQR c | P Value d | Polymorphism | Genotype  | N    | Median Days to Reach Therapeutic Range b ± IQR c | P Value d |
|--------------|-----------|------|-----------------------------------------------|-----------|--------------|-----------|------|-----------------------------------------------|-----------|
| CYP2C9*2     | CC        | 231  | 228.00 ± 295.00 Ref.                          | CYP1A2*1F | CC           | 17       | 221.00 ± 267.00 Ref.                          |           |
|              | CT        | 48   | 266.50 ± 265.25 .696                          | (rs762551) | CA           | 106      | 223.00 ± 221.50 .742                          |           |
|              | TT        | 0    | ND                                              | AA        | 156          | 239.00 ± 326.00 .780                          |           |
|              | CC vs CT  | 231  | 228.00 ± 295.00 Ref.                          | CC vs CA  | 17           | 221.00 ± 267.00 Ref.                          |           |
|              | TT        | 0    | ND                                              | AA        | 156          | 239.00 ± 326.00 .780                          |           |
|              | CC + CT   | 279  | 229.00 ± 293.00 Ref.                          | CC + CA  | 123          | 222.00 ± 233.00 Ref.                          |           |
|              | TT        | 0    | ND                                              | AA        | 156          | 239.00 ± 326.00 .780                          |           |
| CYP2C9*3     | CC        | 260  | 222.50 ± 268.25 Ref.                          | CYP4F2    | CC           | 164      | 226.50 ± 296.25 Ref.                          |           |
|              | CA        | 17   | 316.00 ± 502.00 .026                          | (rs2108622) | CT           | 97       | 208.00 ± 271.00 .351                          |           |
|              | AA        | 2    | 449.00                                          | TT        | 18           | 335.50 ± 218.25 .108                          |           |
|              | CC vs CA  | 260  | 222.50 ± 268.25 Ref.                          | CC vs CT  | 164          | 226.50 ± 296.25 Ref.                          |           |
|              | AA        | 1    | 19.00                                           | AA        | 115          | 234.00 ± 286.00 .753                          |           |
|              | CC + CA   | 277  | 228.00 ± 288.00 Ref.                          | CC + CT  | 261          | 222.00 ± 291.50 .574                          |           |
|              | AA        | 2    | 449.00                                          | AA        | 18           | 335.50 ± 218.25 .108                          |           |
| VKORC1       | GG        | 79   | 203.00 ± 285.00 Ref.                          | MDR1      | GG           | 37       | 203.00 ± 201.00 Ref.                          |           |
|              | GA        | 143  | 228.00 ± 271.00 .580                          | (rs1045642) | GA           | 135      | 240.00 ± 299.00 .074                          |           |
|              | AA        | 57   | 251.00 ± 340.00 .241                          | AA        | 107          | 244.00 ± 305.00 .099                          |           |
|              | GG vs GA  | 79   | 203.00 ± 285.00 Ref.                          | GG vs GA  | 37           | 203.00 ± 201.00 Ref.                          |           |
|              | AA        | 7    | 200.00 ± 295.25 .392                          | AA        | 242          | 241.50 ± 299.25 .666                          |           |
|              | GG + GA   | 222  | 224.00 ± 272.75 Ref.                          | GG + GA   | 172          | 222.50 ± 269.25 .576                          |           |
|              | AA        | 2    | 57.00                                           | AA        | 107          | 244.00 ± 305.00 .552                          |           |
| VKORC1       | CC        | 135  | 216.00 ± 326.00 Ref.                          | CYP3A4*1B | CC           | 248      | 221.00 ± 284.25 .245                          |           |
|              | CT        | 115  | 240.00 ± 257.00 .971                          | (rs2740574) | CT           | 29       | 289.00 ± 298.50 .122                          |           |
|              | TT        | 29   | 185.00 ± 209.50 .364                          | TT        | 2            | 661.50 ± .255                                 |           |
|              | CC vs CT  | 135  | 216.00 ± 326.00 Ref.                          | CC vs CT  | 248          | 221.00 ± 284.25 .245                          |           |
|              | TT        | 2    | 144.00 ± 267.75 .732                          | TT        | 31           | 289.00 ± 308.00 .078                          |           |
|              | CC + CT   | 250  | 230.00 ± 295.75 Ref.                          | CC + CT   | 277          | 228.00 ± 288.00 Ref.                          |           |
|              | TT        | 2    | 29.00 ± 209.50 .398                           | TT        | 2            | 661.50 ± .266                                 |           |
| GGcx         | CC        | 261  | 231.00 ± 294.00 Ref.                          | CYP2C19*2 | AA           | 224      | 230.00 ± 266.25 .351                          |           |
|              | GG        | 18   | 182.50 ± 265.75 .407                          | (rs4244285) | AG           | 53       | 228.00 ± 398.50 .758                          |           |
|              | CC vs CG  | 261  | 231.00 ± 294.00 Ref.                          | AA vs AG  | 224          | 230.00 ± 266.25 .351                          |           |
|              | GG        | 0    | 18.00                                           | AA        | 55           | 228.00 ± 379.00 .724                          |           |
|              | CC + CG   | 279  | 229.00 ± 293.00 Ref.                          | AA + AG   | 277          | 229.00 ± 297.00 Ref.                          |           |
|              | GG        | 0    | 18.00                                           | AA        | 2            | 279.00 ± .778                                 |           |

Abbreviations: INR, international normalized ratio; NA, not applicable; ND, no data available; Ref., reference.

\(^{a}\)N = 279.

\(^{b}\)Therapeutic range = INR 2.0-3.0.

\(^{c}\)IQR: Interquartile range.

\(^{d}\)P < .05 is considered as statistically significant.

Overweight and obesity are important risk factors for cardiovascular disease. Strikingly, TtTR varied from 30 to 2531 days, with an average of 335 and median of 229 days. Patients are at high risk of stroke or hemorrhage during this time. This wide range of TtTR may explain the lack of significance of some variants in the comparative statistical analysis shown in Table 4. However, several interesting observations can be highlighted. The CYP2C9*3 (rs1057910) A allele is significantly associated with higher TtTR in the codominant (P = .026) and dominant models (P = .014), demonstrating a crucial role of this enzyme in acenocoumarol metabolism. Furthermore, there is a clear tendency toward a longer TtTR among patients carrying the CYP4F2 TT genotype, MDR1 A allele, CYP1A2 AA genotype, and CYP3A4 T allele, suggesting that these variants may also have a role in TtTR for this drug. Of course, larger and better controlled retrospective studies will be needed to corroborate this finding. Conversely, the VKORC1 rs7294 and rs9923231, CYP2C9*2 (rs1799853), CYP1A2*1F (rs762551), CYP2C19*2 (rs4244285), and GGcx (rs11676382) variant alleles do not seem to correlate with TtTR, suggesting that these polymorphisms do not affect the time needed to reach a therapeutic dose (INR 2.0-3.0). In some cases, the low number of patients carrying the genotype (eg, GGcx rs11676382 GG and CYP2C9 TT) or haplotype (CYP2C9*2/*3) did not allow for statistical association analyses (data not shown).
To analyze interactions among genotypes and TtTR, we performed a multivariate linear regression using a forward stepwise procedure based on the results from the univariate linear regression analysis, as suggested in the biostatistical literature. Table 5 shows that a multivariate model including MDR1 (rs1045642), CYP4F2 (rs2108622), CYP3A4*1B (rs2740574), CYP1A2*1F (rs762551), and CYP2C9*3 (rs1057910) variant alleles explained only 4.12% of the variation in TtTR (adjusted R²) in the population studied. This is a low level of explanation, but we were not able to find any other study worldwide to which we might compare this result. This model seems to be the first reported for TtTR and VKA-related pharmacokinetic/pharmacodynamic genetic polymorphisms.

In addition, it is well known that ethnicity plays an important role in the pharmacokinetics and pharmacodynamics of drugs, 32-36 and it might be assumed that the situation is even more complex in “mestizo” groups such as South American populations. As a first step, we compared the allele frequencies for the polymorphisms analyzed in our study population with those reported in international studies on patients treated with anticoagulants (Table 6). We did not find any data for CYP1A2*1F (rs762551), CYP2C19*2 (rs4244285), CYP3A4*1B (rs2740574), or GG CX (rs11676382) in patients treated with VKA. Interestingly, however, the allele frequencies for VKORC1 rs9923231 and CYP2C9*2 (rs1799853) in our investigation were similar to values from studies performed in Puerto Rico and Colombia, suggesting similarities among patients from these Latin American regions. In contrast, there are apparent differences between the allele frequencies found here and those reported for an African American population, likely attributable to the differences in ethnic background between the 2 study groups. The Chilean population is largely a mixture of Native Americans and Caucasians (mostly Spaniards), and persons of African American descent or “afrochilenos” do not contribute significantly to the admixture, 41 although this situation has changed notably over the last 5 years due to an increase in immigrants of African descent (mainly from Venezuela, Peru, Haiti, and Colombia). 42

This study has some limitations. Although we had a relatively appropriate sample size, the small number of patients could mask associations, especially for polymorphisms with a low minor allele frequency in this population (CYP2C9*2, CYP2C9*3, and GG CX rs11676382). Furthermore, Chile has not yet developed official standards for anticoagulant therapy (although these guidelines are in progress). Therefore, the

### Table 5. Multivariate Linear Regression Analysis Between the Time to Reach the Therapeutic Range and Genetic Polymorphisms.

| Polymorphism          | Coefficient | Standard error | P Value | CI (95%)     |
|-----------------------|-------------|----------------|---------|--------------|
| MDR1 (rs1045642): GG vs GA + AA | 0.147       | 0.069          | .034    | 0.012 to 0.283 |
| CYP4F2 (rs2108622): CC + CT vs TT | 0.118       | 0.096          | .222    | -0.072 to 0.307 |
| CYP3A4*1B (rs2740574): CC vs CT + TT | 0.115       | 0.074          | .122    | -0.031 to 0.262 |
| CYP1A2*1F (rs762551): CC + CA vs AA | 0.067       | 0.047          | .155    | -0.026 to 0.160 |
| CYP2C9*3 (rs1057910): CC vs CA + AA | 0.209       | 0.094          | .027    | 0.024 to 0.394 |
| CONSTANT              | 1.638       | 0.180          | <.001   | 1.283 to 1.992 |

Abbreviation: CI, confidence interval.

*P < .05 is considered as statistically significant.

### Table 6. Comparison of Minor Allele Frequencies (MAF) Obtained in this Study With Those Obtained in Patients Undergoing VKA Treatment in Spain, Puerto Rico, Brazil, Colombia, and African American Patients.

| Allelic Frequency | Chile (This Study) | Spain 18 | Puerto Rico 16 | Brazil 17 | Colombia 19 | African American 14 | Italia 37 | United Kingdom 38 | China 39 | India 40 |
|-------------------|--------------------|----------|----------------|-----------|-------------|---------------------|-----------|-------------------|---------|---------|
| VKORC1 (rs9923231) | 0.46               | 0.372    | 0.479          | 0.325     | 0.441       | 0.091               | 0.395     | 0.373             | 0.117   | 0.240   |
| VKORC1 (rs7294)    | 0.31               | ND       | ND             | ND        | ND          | ND                  | ND        | ND                | ND      | ND      |
| CYP2C9*2 (rs1799853) | 0.09           | 0.172    | 0.107          | ND        | 0.077       | 0.006               | 0.149     | 0.138             | 0.000   | 0.040   |
| CYP2C9*3 (rs1057910) | 0.04           | 0.151    | 0.043          | ND        | 0.070       | 0.007               | 0.079     | 0.035             | 0.063   | 0.070   |
| CYP4F2 (rs2108622) | 0.24               | 0.382    | ND             | 0.291     | 0.322       | 0.072               | ND        | ND                | 0.260   | ND      |
| ABCB1 (rs1045642)  | 0.63               | 0.864    | ND             | 0.435     | ND          | ND                  | ND        | ND                | 0.374   | ND      |

Abbreviations: ND, no data available in patients with treatment with VKA; VKA, vitamin K antagonist.
starting dose is empirical, based on clinical criteria. This approach increases the variability of the dosage and concomitantly the variability in TTTR, as dosing depends partly on the clinical center and attending physician. Moreover, some patients eventually drift back out of range after reaching a therapeutic INR (2.0-3.0, three consecutive measurements) due to factors such as use of over-the-counter medications, changes in bowel flora or bowel function due to intercurrent or chronic diseases, and poor compliance with medication and dietary instructions. These factors were not analyzed in this study. Finally, other potentially relevant genes and polymorphisms were not evaluated in this study, such as calumenin (CALU) rs2290228, an Arg4Gln sequence change recently identified as a candidate involved in the pharmacogenetics of acenocoumarol anticoagulant therapy.41,43.

Conclusion

We found that CYP2C9*3 polymorphisms are associated with TTTR for VKA in Chilean patients and that the CYP4F2 TT genotype, MDR1 A allele, and CYP3A4 T allele are promising variants that merit further analysis. These results advance our understanding of the basis of ethnic variations in drug metabolism and response to oral anticoagulant therapy. We hope that this information on genetic variants that might affect oral anticoagulation treatment will contribute to developing an algorithm for VKA dose adjustment in the Chilean population in the near future. This tool might be used along with INR values to more precisely adjust VKA dosage, thereby improving the quality of anticoagulation therapy as measured through TTR while decreasing the rate of adverse events including stroke, systemic embolism, and bleeding.

Acknowledgments

The authors wish to thank the patients from the Western Metropolitan Health Service (WMHS) in the Santiago and Melipilla provinces for their altruistic collaboration in pursuit of the common welfare. The authors also thank the Latin American Society of Pharmacogenomics and Personalized Medicine (SOLFAGEM) for sponsoring this article.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was partially supported by Roche Diagnostics Chile and CYTED Grant n° 219RT0572.

ORCID ID

Maria Paz Bertoglia  https://orcid.org/0000-0003-3631-0732
Luis Abel Quiñones  https://orcid.org/0000-0002-7967-5320

References

1. World Health Organization. Cardiovascular Diseases. 2019. http://www.who.int/mediacentre/factsheets/fs317/en/. Accessed May 30, 2019.
2. Mozaffarian D. Dietary and policy priorities for cardiovascular disease, diabetes, and obesity: a comprehensive review. Circulation. 2016;133(2):187-225. doi:10.1161/CIRCULATIONAHA.115.018585
3. DEIS. Basic Health Indicators. Chile: DEIS; 2018. http://www.deis.cl/wp-content/uploads/2018/12/IBS-2016.pdf.
4. Barcellona D, Fenu L, Marongiu F. Point-of-care testing INR: an overview. Clin Chem Lab Med. 2017;55(6):800-805.
5. Leite PM, Martins MAP, Castilho RO. Review on mechanisms and interactions in concomitant use of herbs and warfarin therapy. Biomed Pharmacother. 2016;83:14-21.
6. Quiñones L, Roco A, Miranda C. Farmacogenómica: aplicaciones cardiovasculares. Rev Méd Clin Condes. 2015;26(2):198-209.
7. Pengo V, Pogoraro C, Cucchini U, et al. Worldwide management of oral anticoagulant therapy: the ISAM study. J Thromb Thrombolysis. 2006;21(1):73-77.
8. Guyatt GH, AkI EA, Crowther M, et al. Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):7-47.
9. Ageno W, Gallus AS, Wittkowsky A, et al. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis. Am Coll Chest Physicians Evidence-Based Clin Pract Guidel. 2012; (141):e44S-e488S.
10. Nieto E, Suarez M, Roco A, et al. Anticoagulation management with coumarinic drugs in Chilean patients. Clin Appl Thromb Hemost. 2019;25:1-7.
11. Jacobs LG. Warfarin pharmacology, clinical management, and evaluation of hemorrhagic risk for the elderly. Clin Geriatr Med. 2006;22(1):17-32, vii-viii.
12. Johnson J, Claude KE, Gong L, et al. Clinical pharmacogenetics implementation consortium (CPIC) guideline for pharmacogenetics-guided warfarin dosing: 2017 update. Clin Pharmacol Ther. 2017;102(3):397-404.
13. Bosch J, Eikelboom JW, Connolly SI, et al. Rationale, design and baseline characteristics of participants in the cardiovascular outcomes for people using anticoagulation strategies (COMPASS). Trial. Can J Cardiol. 2017;33(8):1027-1035.
14. Wu AH, Wang P, Smith A, et al. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations. Pharmacogenomics. 2008;9:169-178.
15. Johnson JA, Gong L, Whirl-Carrillo M, et al. Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther. 2011;90(4):625-629.
16. Ramos AS, Seip RL, Rivera-Miranda G, et al. Development of a pharmacogenetic-guided warfarin dosing algorithm for Puerto Rican patients. Pharmacogenomics. 2012;13(16):1937-1950.
17. Santos PC, Marcatto LR, Duarte NE, et al. Development of a pharmacogenetic based warfarin dosing algorithm and its performance in
Brazilian patients: highlighting the importance of population-specific calibration. *Pharmacogenomics*. 2015;16(8):865-876.

18. Borobia AM, Lubomirov R, Ramirez E, et al. An acenocoumarol dosing algorithm using clinical and pharmacogenetic data in Chilean patients with thromboembolic disease. *PLoS One*. 2012;7(7):e41360.

19. Galvez JM, Restrepo CM, Contreras NC, et al. Creating and validating a warfarin pharmacogenetic dosing algorithm for Colombian patients. *Pharmacogenomics Pers Med*. 2018;11(2):169-178.

20. Kocael A, Eronat AP, Tüzün ER, et al. Interpretation of the effect of CYP2C9, VKORC1 and CYP4F2 variants on warfarin dosing adjustment in Turkey. *Mol Biol Rep*. 2019;46(2):1825-1833. doi:10.1007/s11033-019-04634-9.

21. Rosendaal FR, Cannegieter SC, van der Meer FJ, et al. A method to determine the optimal intensity of oral anticoagulant therapy. *Thromb Haemost*. 1993;69(3):236-239.

22. Namipashaki A, Razagh-Moghadam Z, Ansari-Pour N. The essentiality of reporting hardy-Weinberg equilibrium calculations in population-based genetic association studies. *Cell J*. 2015;17(2):187-192.

23. Acúa M, Llop E, Rothhammer F. Composición genética de la población chilena: las comunidades rurales de los valles del Elqui, Limari y Choapa. Rev Méd Chil. 2000;128(3):593-600.

24. Iniesta R, Guíñoa E, Moreno V. Análisis estadístico de polimorfismos genéticos en estudios Epidemiológicos. *Gac Sanit*. 2005;19(4):333-341.

25. Fitzmaurice DA, Accetta G, Haas S, et al. Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELD-AF and treated with vitamin K antagonists. *Br J Haematol*. 2016;174(4):610-623.

26. Haas SA, Train C, Llop E, et al. Quality of vitamin K antagonist control and 1-year outcomes in patients with atrial fibrillation: a global perspective from the GARFIELD-AF registry. *Plos One*. 2016;11(10):e0164076.

27. NICE. *Atrial Fibrillation: The Management of Atrial Fibrillation (CG180).* https://www.nice.org.uk/guidance/cg180. Accessed February 02, 2018.

28. Camm AJ, Lip GY, De Caterina R, et al. ESC Committee for Practice Guidelines-CPG; Document Reviewers 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation–developed with the special contribution of the European heart rhythm association. *Eur Heart J*. 2012;14:1385-1413.

29. Corbalán R, Conejeros C, Rey C, et al. Features, management and prognosis of Chilean patients with nonvalvular atrial fibrillation: GARFIELD AF registry. Rev Med Chil. 2017;145:963-971.

30. Verhoef TI, Redekop WK, Daly AK, et al. Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon. *Br J Clin Pharmacol*. 2014;77(4):626-641. doi:10.1111/bcp.12220. Review.

31. National Health Survey. National Health Survey Chile 2016-2017 Sitio. 2017. https://www.minsal.cl/wp-content/uploads/2017/11/ENS-2016-17_PRIMEROS-RESULTADOS.pdf. Accessed January 18, 2019.

32. Dupont WD. *Statistical modeling for biomedical researchers. A Simple Introduction to the Analysis of Complex Data*. 2nd ed. Cambridge, UK: Cambridge University Press; 2009:123.

33. Cavallari LH, Langaebye T, Momary KM, et al. Genetic and clinical predictors of warfarin dose requirements in African Americans. *Clin Pharm Therapeut*. 2010;87(4):459-464.

34. Tavares LC, Marcatto LR, Soares RAG, Krieger JE, Pereira AC, Santos PCJL. Association between ABCB1 Polymorphism and stable warfarin dose requirements in Brazilian patients. *Front Pharmacol*. 2018;9:542.

35. Jiménez Varo E, Cañadas Garre M, Gömez A, et al. The effect of main gene polymorphisms on stable doses of acenocoumarol in long-term anticoagulation treatment. Hospital Universitario Virgen de las Nieves, Pharmacogenetic Unit, Granada, Spain. 2018. Abstract n°: DGI-068. http://www.eahp.eu/sites/default/files/dgi-068.pdf. Accessed August 20, 2019.

36. Kurose K, Sugiyama E, Saito Y. Population differences in major functional polymorphisms of pharmacokinetic/pharmacodynamic-related genes in Eastern Asians and Europeans: implications in the clinical trials for novel drug development. *Drug Metab Pharmacokinet*. 2012;27(1):9-54.

37. Hamberg A, Wadelius M, Lindh JD, et al. A pharmacometric model describing the relationship between warfarin dose and INR response with respect to variations in CYP2C9, VKORC1, and age. *Clin Pharmacol Ther*. 2010;87(6):727-734.

38. Pirmohamed M, Burnside G, Eriksson N, et al. A randomized trial of genotype-guided dosing of warfarin. *N Engl J Med [Internet]*. 2013;369(24):2294-2303. http://www.ncbi.nlm.nih.gov/pubmed/24251363. Accessed August 20, 2019.

39. Liu R, Cao J, Zhang Q, Shi XM, Pan XD, Dong R. Clinical and genetic factors associated with warfarin maintenance dose in northern Chinese patients with mechanical heart valve replacement. *Medicine (Baltimore)*. 2017;96(2):e5658. doi:10.1097/MD. 0000000000005658.

40. Kalpana SR, Bharath G, Manjunath CN, Christopher R. Influence of VKORC1 and CYP2C9 polymorphisms on daily acenocoumarol dose requirement in south Indian patients with mechanical heart valves. *Clin Appl Thromb Hemost*. 2017;23(7):876-882. doi:10.1177/1076029616655617.

41. Pulgar I, Gallo C, Bortolini MC, et al. Gene geography of Chile: regional distribution of American, European and African genetic contributions. *Revista Médica Chilena (Marzo de)*. 2014;142(3):281-289. doi:10.4067/S0034-98872014000300001.

42. Ministry General Secretariat of Government. *Ministry General Secretariat of Government*. Chile; 2019. http://www.msgg.gob.cl/wp/index.php/2019/02/14/ministro-s-de-interior-e-informe-estimacion-de-personas-extranjeras-residentes-en-chile-permite-visi bilizar-a-la-poblacion-de-migrantes-y-construir-politicas-publi cas-que-se-requi/. Accessed August 20, 2019.

43. González-Conejero R, Corral J, Roldán V, et al. The genetic interaction between VKORC1 c1173T and calumenin a29809 g modulates the anticoagulant response of acenocoumarol. *J Thromb Haemost*. 2007;5(8):1701-1706.